This stock is one of several featured in our latest research. For more small-cap opportunities with asymmetric return ...

Arvinas PROTAC protein degraders have some potential, with vepdegestrant as its late-stage, most promising asset, partnered ...

Arvinas Inc. (NASDAQ:ARVN) is one of the best low priced pharma stocks to buy now. Earlier on June 13, Arvinas presented ...

During his tenure as CEO, Dr. Houston has been instrumental in Arvinas’ success moving six programs into the clinic, reporting the results of the first positive pivotal Phase 3 trial for a PROTAC, and ...

Arvinas on Wednesday said Houston, who has been president and chief executive of the New Haven, Conn., company since September 2017, will retire from those positions upon the appointment of a ...

Earlier this year, we talked about why Arvinas stock (NASDAQ: ARVN), a biopharmaceuticals company focused on oncology treatments based on targeted protein degradation, is vulnerable to downside risk.

Summary. Arvinas' shares have experienced a significant increase, up more than 75% since November 2023, due to the success of its lead asset, vepdegestrant, in breast cancer studies.

Arvinas has advanced ARV-471 to a Phase 2 dose expansion trial testing it in patients with locally advanced or metastatic breast cancer that is ER positive and HER2 negative.

Arvinas Inc is today’s second Top Short. Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases.

NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today ...

Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements.